Renaissance of farnesyltransferase inhibitors in cancer

József Tímár, Balázs Hegedűs, Marcell Baranyi · 2026

Read Renaissance of farnesyltransferase inhibitors in cancer by József Tímár, Balázs Hegedűs, Marcell Baranyi (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13422314.txt.

Description

József Tímár and colleagues review the comeback of farnesyltransferase inhibitors in cancer in a 2026 paper. Early trials failed because the drugs were given without markers to pick responders, stalling the field. Two approvals revived interest, lonafarnib for childhood progeria and tipifarnib for HRAS-mutant head and neck cancer.

New lab work shows these inhibitors can boost KRAS blockers and other targeted drugs, giving the class a second chance in combination therapy. The review insists future trials must use predictive markers, or they risk repeating the first generation's costly mistake.

Catalog record

CREATORJózsef Tímár, Balázs Hegedűs, Marcell Baranyi
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE32 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13422314

Browse the full library · About the Tower of Babel